Association between Interleukin-6 Levels, Rituximab Response, and Disease Activity in Patients with Rheumatoid Arthritis
DOI:
https://doi.org/10.32947/ajps.v25i3.1225Keywords:
interleukin-6, rheumatoid arthritis, response, rituximabAbstract
Background: Interleukin-6 (IL-6) significantly affects rheumatoid arthritis (RA) and its associated conditions, playing a crucial role in acute inflammation by promoting the synthesis of most acute-phase proteins.
Aim: The present study aimed to assess the potential association between Rituximab (RTX) response and IL-6 level in RA patients
Patients and method: The current study was conducted in Baghdad-Iraq during the period from January to March 2023. The study included a convenient sample of ninety adult patients who were already diagnosed with RA and received intravenous infusions of RTX for at least six months. Clinical Disease Activity Index (CDAI) was adopted to evaluate RA activity.
Results: The proportion of patients with high disease activity according to CDAI was significantly higher in the RTX non-responders group compared to the RTX responders’ group. The IL-6 level was significantly higher in the RTX non-responders’ group than in the RTX responders’ group (P-value<0.001). The IL-6 level was significantly higher in patients with high disease activity than other patients.
Conclusion: In RA patients who treated with RTX, IL-6 levels are correlated with increased clinical disease activity and may be used as a proxy for RTX responsiveness in RA patients.
References
1- Sheet MM, Kamel LA-E, Farhood JN. The Role of Anti-TNFα Therapy in the Amelioration of Disease Burden in Patients with Refractory Rheumatoid Arthritis. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2014;14(1):14-22.https://doi.org/10.32947/ajps.v14i1.121
2- Al-Sarray ZA, Hussein RH, Al-Hafidh AH, Al-Rayahi IA. Vitamin D deficiency Associates with Disease Severity in Rheumatoid Arthritis Patients. Al-Mustansiriyah J. Sci. [Internet]. 2023 Feb. 25;33(5):33-8.
3- Thamer W. Study of some immunological effects of methotrexate in people with rheumatoid arthritis. Al-Qadisiyah Journal Of Pure Science. 2019;24(2).
https://doi.org/10.29350/jops.2019.24.2.957
4- Ball RJ, Avenell A, Aucott L, Hanlon P, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis. Arthritis Research & Therapy. 2015;17(1):274.
https://doi.org/10.1186/s13075-015-0755-6
5- Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2014;1843(11):2563-82.
https://doi.org/10.1016/j.bbamcr.2014.05.014
6- Mohammed M, Hamadi S, Jasim G. Impact of metabolic factors on the incidence and intensity of knee osteoarthritis in a sample of Iraqi patients. Journal of Global Pharma Technology. 2018; 10:971-80.
7- Saadi M, Mohammed M. Evaluation of the Anti-inflammatory Effect of Curcumin as an Additive Therapy to Meloxicam in Management of Knee Osteoarthritis. International Journal of Drug Delivery Technology. 2022; 12:57.
8- Alhendi A, Naser SA. The dual role of interleukin-6 in Crohn's disease pathophysiology. Frontiers in Immunology. 2023;14.https://doi.org/10.3389/fimmu.2023.1295230
9- Mohammed MM, Al-Shamma K, Jasim N. Evaluation of the anti-inflammatory effect of metformin as adjuvant therapy to NSAID (meloxicam) in patients with knee osteoarthritis. Int J Sci Nature. 2014; 5:277-82.
10- Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022;149:155742.https://doi.org/10.1016/j.cyto.2021.155742
11- Fatel ECdS, Rosa FT, Dichi I. Adipokines in rheumatoid arthritis. Advances in Rheumatology. 2019;58.https://doi.org/10.1186/s42358-018-0026-8
12- Sepriano A, Kerschbaumer A, Smolen JS, Van Der Heijde D, Dougados M, Van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the rheumatic diseases. 2020;79(6):760-70.https://doi.org/10.1136/annrheumdis-2019-216653
13- van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. The Journal of Rheumatology. 2015;42(10):1761-6.
https://doi.org/10.3899/jrheum.150051
14- Oldenburg P. Rituximab. Reference Module in Biomedical Sciences. Elsevier. 2018.https://doi.org/10.1016/B978-0-12-801238-3.97945-5
15- Mohammed NUG, Gorial FI, Khaleel FM, Abed BA, Mutar SA, Farhan LO, et al. Role of Human β-Defensin-3 in Rheumatoid Arthritis: An Observational Single-Center Study . Al-Rafidain J Med Sci. 2023;5(1S): S71-75.
16- Hana DB. Association of Interleukin 6 with Positive Immunohistochemical staining of Estrogen Receptor in Breast Cancer Patients. AJPS. 2010;7(1):106-14.
17- Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Annals of the Rheumatic Diseases. 2014;73(5):909-12.https://doi.org/10.1136/annrheumdis-2013-204417
18- Barahona Correa JE, Franco Cortés, M.A., Ángel Uribe, J. and Rodríguez Camacho, L.S. Comparison of plasma cytokine levels before and after treatment with rituximab in patients with rheumatoid arthritis and systemic lupus erythematosus-associated polyautoimmunity. Universitas Médica. 2018;59(3):21-36.
https://doi.org/10.11144/Javeriana.umed59-3.cyto
19- Garcia-Montoya L, Villota-Eraso C, Yusof MYM, Vital EM, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. The Lancet Rheumatology. 2020;2(8):e497-e509.https://doi.org/10.1016/S2665-9913(20)30033-3
20- Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S. Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis. Biologics: Targets and Therapy. 2012;6(null):31-5.https://doi.org/10.2147/BTT.S27840
21- Almeida-Santiago C, Quevedo-Abeledo JC, Hernández-Hernández MV, de Vera-González A, González-Delgado A, González-Gay MÁ, et al. Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis. Life. 2023;13(1):82.https://doi.org/10.3390/life13010082
22- Rajaei E, Mowla K, Hayati Q, Ghorbani A, Dargahi-Malamir M, Hesam S, et al. Evaluating the Relationship Between Serum Level of Interleukin-6 and Rheumatoid Arthritis Severity and Disease Activity. Current Rheumatology Reviews. 2020;16(3):249-55.https://doi.org/10.2174/1573397115666190206144223
23- De Lima CAD, Rushansky E, Adelino JE, de Oliveira Souza AP, d'Emery Alves Santos P, de Araújo Mariano MHQ, et al. Are key cytokines genetic and serum levels variations related to rheumatoid arthritis clinical severity? Gene. 2020; 722:144098.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Aya Fawzi Talib, Mohammed Mahmood Mohammed, Ghaith Bahader
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
